Skip to content

Study · Non-randomized trial · n = 9 · 1986

2 results

Cranial irradiation for cerebral and nasopharyngeal tumours in children: evidence for the production of a hypothalamic defect in growth hormone release.

Blacklay A, Grossman A, Ross RJ, Savage MO, Davies PS, Plowman PN, Coy DH, Besser GM

The Journal of endocrinology1 Jan 1986Cited by 31 (Europe PMC)

PMID2868066 (opens in a new tab)DOI10.1677/joe.0.1080025 (opens in a new tab)PepBankPUB-02868066
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In nine children irradiated for brain and nasopharyngeal tumours and deficient in GH, serum GH rose after GHRH(1-29)NH2 in all children.

    In plain wordsIn nine irradiated children who lacked growth hormone, a dose of the GHRH peptide made growth hormone rise in every child.

    Peptide
    Sermorelin
    Outcome
    IncreaseSerum GH response to GHRH(1-29)NH2
    Study

    n = 9

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum GH rose in response to GHRH(1-29)NH2 in all the children, and in five the peak serum GH response was greater than 20 mu./l.
    1 context sentence
    Summary · context
    We have studied the GH response to GHRH(1-29)NH2 in nine children irradiated for brain and nasopharyngeal tumours, who were not growing and were deficient in GH as assessed by insulin-induced hypoglycaemia.
  2. 02HumanNon-randomized trialEfficacy outcome

    In five of nine irradiated children, the peak serum GH response to GHRH(1-29)NH2 was greater than 20 mu./l.

    In plain wordsIn five of nine irradiated children, growth hormone after the GHRH peptide rose above 20 mu/l.

    Peptide
    Sermorelin
    Outcome
    IncreaseChildren with peak serum GH above 20 mu/l
    Study

    n = 9

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    in five the peak serum GH response was greater than 20 mu./l.
    1 context sentence
    Summary · context
    We have studied the GH response to GHRH(1-29)NH2 in nine children irradiated for brain and nasopharyngeal tumours, who were not growing and were deficient in GH as assessed by insulin-induced hypoglycaemia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.